Is BrainsWay Ltd. (BWAY) a Buy, Sell, or Hold?
NASDAQ : BWAY
BrainsWay Ltd. — Insider Trades
$16.15 USD
-$0.35 (-2.12%)
- Volume
- 127.71K
- Average Volume
- 117.75K
- Market Capitalization
- $633.45M
- P/E Ratio
- 73.03
- Dividend Yield
- 0.00%
- Price Target
- $15.00
- Year High
- $17.35
- Year Low
- $5.68
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.34
Insider Activity Summary (Last 12 Months)
Insiders Buying
2
Insiders Selling
6
Amount of Insider Selling
$55000
BWAY Insider Buying/Selling by Quarter
BWAY Insider Trading History
| Insider Name | Title | Date | Transaction | Cost | Filing Date |
|---|---|---|---|---|---|
| Moiseyev Gilad | officer: Chief Technology Officer | 2026-05-25 | M-Exempt | 0 | 2026-06-22 |
| Moiseyev Gilad | officer: Chief Technology Officer | 2026-05-25 | F-InKind | 0 | 2026-06-22 |
| Moiseyev Gilad | officer: Chief Technology Officer | 2026-06-15 | S-Sale | 0 | 2026-06-22 |
| Moiseyev Gilad | officer: Chief Technology Officer | 2026-05-25 | M-Exempt | 0 | 2026-06-22 |
| Mitrany Rayten Michal Ety | director | 2026-05-25 | S-Sale | 0 | 2026-05-26 |
| Mitrany Rayten Michal Ety | director | 2026-05-26 | S-Sale | 0 | 2026-05-26 |
| Mitrany Rayten Michal Ety | director | 2026-05-20 | M-Exempt | 0 | 2026-05-21 |
| Mitrany Rayten Michal Ety | director | 2026-05-20 | F-InKind | 0 | 2026-05-21 |
| Mitrany Rayten Michal Ety | director | 2026-05-19 | M-Exempt | 0 | 2026-05-21 |
| Mitrany Rayten Michal Ety | director | 2026-05-19 | F-InKind | 0 | 2026-05-21 |
| Mitrany Rayten Michal Ety | director | 2026-05-19 | M-Exempt | 0 | 2026-05-21 |
| Mitrany Rayten Michal Ety | director | 2026-05-20 | M-Exempt | 0 | 2026-05-21 |
| Zangen Abraham | director | 2026-03-18 | 0 | 2026-03-18 | |
| Zangen Abraham | director | 2026-03-18 | 0 | 2026-03-18 | |
| Mitrany Rayten Michal Ety | director | 2026-03-18 | 0 | 2026-03-18 | |
| Mitrany Rayten Michal Ety | director | 2026-03-18 | 0 | 2026-03-18 | |
| Zacut David | director | 2026-03-18 | 0 | 2026-03-18 | |
| Zacut David | director | 2026-03-18 | 0 | 2026-03-18 | |
| Zacut David | director | 2026-03-18 | 0 | 2026-03-18 | |
| Zacut David | director | 2026-03-18 | 0 | 2026-03-18 | |
| Marom Ido | officer: Chief Financial Officer | 2026-03-18 | 0 | 2026-03-18 | |
| Marom Ido | officer: Chief Financial Officer | 2026-03-18 | 0 | 2026-03-18 | |
| SARID KAREN | director | 2026-03-18 | 0 | 2026-03-18 | |
| SARID KAREN | director | 2026-03-18 | 0 | 2026-03-18 | |
| Lushi Avner | director | 2026-03-18 | 0 | 2026-03-18 | |
| Lushi Avner | director | 2026-03-18 | 0 | 2026-03-18 | |
| Rozenfeld Naomi | officer: Chief Marketing Officer | 2026-03-18 | 0 | 2026-03-18 | |
| Rozenfeld Naomi | officer: Chief Marketing Officer | 2026-03-18 | 0 | 2026-03-18 | |
| Levy Hadar | officer: Chief Executive Officer | 2026-03-18 | 0 | 2026-03-18 | |
| Levy Hadar | officer: Chief Executive Officer | 2026-03-18 | 0 | 2026-03-18 | |
| Roth Yiftach | officer: Chief Scientist | 2026-03-18 | 0 | 2026-03-18 | |
| Hanlon Colleen | officer: VP of Medical Affairs | 2026-03-18 | 0 | 2026-03-18 | |
| Hanlon Colleen | officer: VP of Medical Affairs | 2026-03-18 | 0 | 2026-03-18 | |
| Boehm Amiram | director | 2026-03-18 | 0 | 2026-03-18 | |
| Boehm Amiram | director | 2026-03-18 | 0 | 2026-03-18 | |
| Moiseyev Gilad | officer: Chief Technology Officer | 2026-03-18 | 0 | 2026-03-18 | |
| Moiseyev Gilad | officer: Chief Technology Officer | 2026-03-18 | 0 | 2026-03-18 | |
| Shulkin Jonathan K | director | 2026-03-18 | 0 | 2026-03-18 | |
| Shulkin Jonathan K | director | 2026-03-18 | 0 | 2026-03-18 |